Home
Print
Sitemap
IntranetNews
- ThromboGenics announces that the FDA intends to grant Ocriplasmin Priority Review
- reMYND receives a positive tax ruling on the income from its Roche collaboration
- ThromboGenics submits biologics license application for ocriplasmin to the U.S. FDA
- ThromboGenics and BioInvent complete enrollment of Phase IIb trial with TB-402 ahead of schedule
- ThromboGenics appoints Thomas Clay as new board member
- ThromboGenics: business update
- Option: trading update 3rd quarter 2011
- Julia Haller presents ocriplasmin phase III Responder analysis at AAO
- ThromboGenics: EMA acceptance
- reMYND: Scrip Award nomination
- ThromboGenics: business update
- ThromboGenics announces new phase III ocriplasmin data presented at the 2011 annual meeting of the American Society of Retina Specialists
- ThromboGenics on track to file ocriplasmin by end of 2011
- IWT helps to accelerate reMYNDs Diabetes program with a grant of 1.48 million EUR for 2011-2012
- Second Leuven Bio-incubator meets increasing demand for specialised office and lab space
- ThromboGenics and BioInvent treats first patient with novel antibody anti-cancer agent
- ThromboGenics business update
- Leuven.Inc calendar
- News on life sciences
- ThromboGenics and BioInvent dose the first patient with TB-402 for venous thromboembolism prophylaxis
- FORMAC obtains EMA Orphan Drug Designation for FP110